Učitavanje...
Insight into the role of p62 in the cisplatin resistant mechanisms of ovarian cancer
Cisplatin is a platinum-based first-line drug for treating ovarian cancer. However, chemotherapy tolerance has limited the efficacy of cisplatin for ovarian cancer patients. Research has demonstrated that cisplatin causes changes in cell survival and death signaling pathways through its interaction...
Spremljeno u:
| Izdano u: | Cancer Cell Int |
|---|---|
| Glavni autori: | , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
BioMed Central
2020
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7164250/ https://ncbi.nlm.nih.gov/pubmed/32322174 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12935-020-01196-w |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|